A promising molecule can survive a bad metaphor. A young biotech usually cannot. SCIENT built its business around the awkward, consequential work of making complicated science understandable before the next investor meeting, clinical milestone, or corporate turning point.
A clinical result is not yet an investment case. For nearly four decades, Burns McClellan has worked in the narrow, consequential gap between the laboratory and the capital markets.